Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Adv Exp Med Biol. 2021;1312:165-177. doi: 10.1007/5584_2020_596.
Stem cell-based therapy stands as a robust experimental treatment for ischemic stroke. Stem cells derived from fetal, embryonic, and adult tissues serve as potential sources for transplantable cells in the setting of ischemic stroke. However, the search continues for finding an optimal cell line for clinical use. Muse cells, a distinct subset of mesenchymal stem cells found sporadically in the connective tissue of nearly every organ, may be a suitable candidate due to its safety and accessibility. These cells have been investigated for therapeutic usage in chronic kidney disease, liver disease, acute myocardial infarction, and stroke. Muse cells display the ability to engraft and differentiate into the host neural network unlike many other cell lines which only display bystander immunomodulating effects. Taking advantage of this unique engraftment and differentiation mechanism behind Muse cells' therapeutic effects on the central nervous system, as well as other organ systems, will undoubtedly advance the cells' utility for cell-based regenerative medicine in stroke.
基于干细胞的疗法是一种强大的实验性缺血性中风治疗方法。源自胎儿、胚胎和成人组织的干细胞作为缺血性中风环境中可移植细胞的潜在来源。然而，人们仍在继续寻找用于临床应用的最佳细胞系。Muse 细胞是间充质干细胞的一个独特亚群，在几乎每个器官的结缔组织中偶尔会发现，由于其安全性和可及性，可能是一个合适的候选细胞。这些细胞已被用于慢性肾脏病、肝病、急性心肌梗死和中风的治疗用途。与许多其他仅显示旁观者免疫调节作用的细胞系不同，Muse 细胞具有植入和分化为宿主神经网络的能力。利用 Muse 细胞对中枢神经系统以及其他器官系统的治疗效果背后的这种独特的植入和分化机制，无疑将提高细胞在中风的基于细胞的再生医学中的应用。
